Often, it is not the lack of groundbreaking ideas that prevents the development of novel, innovative anti-infective drugs - a lack of funding, development and business experience limits resources for start-ups and scientific groups, discouraging the development of new therapeutic options.
AiCuris strongly believes that there is a need to encourage the development of more early projects based on new scientific principles to fill pipeline gaps, tackle AMR and prevent future pandemics. Therefore, we are constantly searching for novel technologies and creative approaches to develop more effective treatments against infectious diseases with high medical needs.
To promote early ideas that might lead to the next resistant breaking antibiotic or anti-infective, AiCuris has launched AiCubator, an innovative corporate incubator that provides long-term support for such anti-infective research projects.
Every year AiCuris selects up to three projects that are scientifically attractive but too early staged for licensing deals. These projects should focus on areas of high priority in the field of anti-infectives.